APR 07, 2016 10:30 AM PDT

Airbrushing the Poster Child: How ACOG's 2016 cervical cancer screening practice bulletin may impact molecular testing

3 6 430

  • Senior Director, Scientific Affairs at Roche Molecular Diagnostics
      Dr. Ed Baker trained received his medical training in the Loma Linda University system. After completing his specialty training in Obstetrics and Gynecology, he practiced in the San Francisco bay area as a community physician for nearly 10 years. In 2002 he became interested in drug development and took a position with Organon Pharmaceuticals which was one of the most active companies focused on Women's health and eventually became the head of the women's health franchise Medical Affairs team.
      Dr. Baker has been involved in the development and registration of dozens of products for women's health and often lectures and writes on a variety of topics related to women's health. He has taken leadership positions for companies focused on areas outside of women's health. Prior to his current position he was head of Medical Affairs at Actelion Pharmaceuticals, a company that focused its efforts on rare diseases. He was attracted to his current position at Roche Molecular diagnostics because it presents a great opportunity to help shift a longstanding paradigm in cervical cancer screening. Dr. Baker remains a board certified OB/GYN and holds an appointment as Associate Professor of Medicine in the OB/GYN department at UC Davis.


    Cervical cancer screening has been the 20th century poster child for preventative screening.  This presentation is a gynecologist’s perspective on its continuing evolution –both as a great success and an opportunity for improvement.    Dr Baker will focus on the transition from experience based to data driven development of guidelines for physicians.  He will also reflect on the challenges for molecular laboratories.   Their anticipation of changes in screening practice and potential impact to their range of services including consultative role to OB/Gyn physicians.  
    Learning objectives:
    1) The attendee will understand how and why the approach to cervical cancer screening is evolving.
    2) The attendee will understand how these changes might impact the molecular lab and it's relationship with OB/GYNs.

    Show Resources
    Loading Comments...